Sartorius : Conference Call 9M|2021 Presentation

Conference Call

9M 2021 Results

Joachim Kreuzburg, Rainer Lehmann

Sartorius | Sartorius Stedim Biotech | October 20, 2021

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.

This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

2

Highlights 9M 2021

• Both divisions with dynamic double-digit growth in order intake, sales and earnings
• Strong core growth plus significant pandemic-related demand and positive development of acquisitions
• Acquisition of Xell AG strengthens cell culture media portfolio for advanced therapies and vaccines
• Forecast for 2021, raised in July, confirmed

3

Agenda

Sartorius Group

9M 2021 results | FY 2021 guidance

Sartorius Stedim Biotech Group

9M 2021 results | FY 2021 guidance

Questions & Answers

4

Double-digit growth in sales, order intake and earnings

Sartorius Group	9M 2020	9M 2021	in %	in % cc1
in millions of € unless otherwise specified
Sales revenue	1,680.0	2,526.9	+50.4	+53.9
Order intake	1,956.5	3,286.2	+68.0	+72.3
Underlying EBITDA2	488.7	866.4	+77.3
Underlying EBITDA2 margin in %	29.1	34.3	+5.2pp
Underlying EPS3 (ord.) in €	3.08	5.94	+92.7
Underlying EPS3 (pref.) in €	3.09	5.95	+92.4

• Acquisitions contribute around 6pp to sales growth; net effect from pandemic about 21pp / about 20pp for order intake
• Underlying EBITDA margin driven by economies of scale and by partially deferred cost development

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

5